Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
NVDA -0.4EWJ 0.37TECK.B.TO -2.09CNQ.TO 0.71HHL.TO 0.075SYLD 0.03HAC.TO 0.04TRU -0.01
Daily Stock Opinions and Ratings
Stockchase Opinions

Rob Sechan, Managing Partner, New Edge CapitalVertex Pharmaceuticals Inc.VRTXBUYAug 19, 2022

Bought this, adding to his healthcare holdings, a defensive sector he likes. Strong balance sheet with a deep pipeline of drugs, 20x 2023 earnings, 50% operating margins, and 5% free cash flow yield.
Rob Sechan, Managing Partner, New Edge CapitalRob Sechan, Managing Partner, New Edge Capital
Owned
Unlock Rating
$297.67

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

BUY

Vertex Pharmaceuticals Inc.(VRTX)

Jan 29, 2024

PPH, an ETF for pharma producers, is breaking out and near a record. VTX and Eli Lilly are leaders in this space and Vertex has a great product for Cystic Fibrosis therapeutics. It is growing well and not too expensive.

Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$435.90

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Vertex Pharmaceuticals Inc.(VRTX)

Nov 16, 2023
(A Top Pick Jan 04/22, Up 57.9%)Stochchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX has triggered its stop at $350.  To remain disciplined, we recommend covering the position at this time.  This will result in a net investment gain of 44%, when combined with our previous recommendations.

Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$342.97

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Vertex Pharmaceuticals Inc.(VRTX)

Nov 07, 2023
(A Top Pick Jan 04/22, Up 88.8%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $330) to $350 at this time.  

Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$383.02

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
BUY

Vertex Pharmaceuticals Inc.(VRTX)

Oct 13, 2023

They're in the MS business, so will they expand beyond MS? HE's confident they will and have some hit drugs.

Photo of Jim LebenthalJim LebenthalUnlock Rating
$371.00

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
PARTIAL SELL

Vertex Pharmaceuticals Inc.(VRTX)

Sep 11, 2023

A high-quality biopharma with a strong cystic fibrosis drug. Are trying to get into other franchises like diabetes treatments. Will do well long-run. Trades at 23x with 11% earnings growth, so you can take some profits now. Had a good run, so take some money off the table.

Photo of Jim LebenthalJim Lebenthal
Owned
Unlock Rating
$347.26

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Vertex Pharmaceuticals Inc.(VRTX)

Aug 29, 2023
(A Top Pick Jan 04/22, Up 72.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  To be disciplined, we recommend trailing up the stop (from $320) to $330 at this time.  

Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$350.55

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
BUY

Vertex Pharmaceuticals Inc.(VRTX)

Jul 28, 2023

Not too expensive. They report next week. They have good momentum and products.

Photo of Jim LebenthalJim LebenthalUnlock Rating
$354.93

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Vertex Pharmaceuticals Inc.(VRTX)

Jun 29, 2023
(A Top Pick Jan 04/22, Up 71.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  We now recommend to trail up the stop (from $300) to $320.  

Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$348.26

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Vertex Pharmaceuticals Inc.(VRTX)

May 02, 2023
(A Top Pick Jan 03/23, Up 57.2%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  We recommend trailing up the stop to $300 at this time.  

Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$346.66

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
BUY

Vertex Pharmaceuticals Inc.(VRTX)

Apr 12, 2023

New for him. Are diversifying away from Cystic Fibrosis drugs into other treatments.

Photo of Jim LebenthalJim Lebenthal
Owned
Unlock Rating
$326.69

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Vertex Pharmaceuticals Inc.(VRTX)

Oct 06, 2022
(A Top Pick Jan 04/22, Up 34.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX is progressing well. To remain disciplined, we recommend trailing up the stop (from $270) to $280.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$298.39

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
TOP PICK

Vertex Pharmaceuticals Inc.(VRTX)

Sep 26, 2022
It is in the biotech sector which came under pressure18 months ago. The sector found a footing in June and has held well above lows while the market is selling off. In general there are great bio technologies coming to market. Specifically it is a leading producer of a Cystic Fibrosis treatment that continues to proliferate around global health care systems. It is head and shoulders over what was available previously. It is a defensive stock because earnings are not cyclical and it is growing at 25% per year as well as trading at 18X next year's earnings. With a 74 billion market cap it just made a 5 year high which is very significant. (Analysts’ price target is $310.80)
Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$276.78

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Vertex Pharmaceuticals Inc.(VRTX)

Sep 13, 2022
(A Top Pick Jan 04/22, Up 29.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK is progressing well. We now recommend trailing up the stop (from $245) to $270.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$286.15

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
TOP PICK

Vertex Pharmaceuticals Inc.(VRTX)

Aug 11, 2022
Biotech. Dominant drug for CF treatment. Exceedingly strong growth profile, with 2022 estimate for 40% earnings growth. Working on a compound for acute pain that's not addictive. Technically way outperformed the biotech group. Now there's strength in the group and the market. No dividend. (Analysts’ price target is $307.75)
Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$293.43

Stock price when the opinion was issued

$452.10

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
The ultimate 360° Tracker Your financial life in one place, automatically

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VEEV 0$153.3
WSP.TO 1.13$176.7
VRTX 0.47$452.1
OTEX.TO 0.24$29.47
CCO.TO 0.61$151.07

Today's Top Picks

NVDA -0.4$210.29
EWJ 0.37$96.63
TECK.B.T… -2.09$88.93
CNQ.TO 0.71$58.66
HHL.TO 0.075$6.865

Popular Articles

Latest Sell Signals

TD.TO 0.7$169.33
MBLY -0.03$8.43
ASAN 0.03$6.95
MODG -0.01$18.21
NVTS 0$24.02

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Brian Acker, CA

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica